Joerg Huelsken

Dr. Joerg Huelsken


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
TFTea Fevr
Tea Fevr
SRSylvie Robine
Sylvie Robine
DLDaniel Louvard
Daniel Louvard
JHJoerg Huelsken
Joerg Huelsken
The Wnt signaling pathway is deregulated in over 90% of human colorectal cancers. β-Catenin, the central signal transducer of the Wnt pathway, can directly modulate gene expression by interacting with transcription factors of the TCF/LEF family. In the present study we investigate the role of Wnt signaling in the homeostasis of intestinal epithelium by using tissue-specific, inducible β-catenin gene ablation in adult mice. Block of Wnt/β-catenin signaling resulted in rapid loss of transient-amplifying cells and crypt structures. Importantly, intestinal stem cells were induced to terminally differentiate upon deletion of β-catenin, resulting in a complete block of intestinal homeostasis and fatal loss of intestinal function. Transcriptional profiling of mutant crypt mRNA isolated by laser capture microdissection confirmed those observations and allowed us to identify genes potentially responsible for the functional preservation of intestinal stem cells. Our data demonstrate an essential requirement of Wnt/β-catenin signaling for the maintenance of the intestinal epithelium in the adult organism. This challenges attempts to target aberrant Wnt signaling as a new therapeutic strategy to treat colorectal cancer.

1 April 2008 in Nature
Verified
Journal Article
Closed access
IMIlaria Malanchi
Ilaria Malanchi
Hector PeinadoHector Peinado
Hector Peinado
DKDeepika Kassen
Deepika Kassen
THThomas Hussenet
Thomas Hussenet
DMDaniel Metzger
Daniel Metzger
JHJoerg Huelsken
Joerg Huelsken

1 December 2015 in Cancer Cell
Verified
Journal Article
Closed access
POPaloma Ordóñez-Morán
Paloma Ordóñez-Morán
CDCaroline Dafflon
Caroline Dafflon
MIMasamichi Imajo
Masamichi Imajo
ENEisuke Nishida
Eisuke Nishida
JHJoerg Huelsken
Joerg Huelsken

1 August 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
JAJean-Paul Abbuehl
Jean-Paul Abbuehl
ZTZuzana Tatarova
Zuzana Tatarova
WHWerner Held
Werner Held
JHJoerg Huelsken
Joerg Huelsken

1 June 2023 in Cell Stem Cell
Verified
Journal Article
Open access
LBLaurent Beziaud
Laurent Beziaud
CYC. Megan Young
C. Megan Young
AAAngela Madurga Alonso
Angela Madurga Alonso
MNMaxim Norkin
Maxim Norkin
AMAnna Rita Minafra
Anna Rita Minafra
JHJoerg Huelsken
Joerg Huelsken
Despite the remarkable success of immune checkpoint blockade (ICB) therapy, most cancer patients still do not respond. We now find that immunotherapy can induce stem-like properties in tumors. Using mouse models of breast cancer, we observe that cancer stem cells (CSCs) show not only enhanced resistance to T cell cytotoxicity, but that interferon gamma (IFNγ) produced by activated T cells directly converts non-CSCs to CSCs. IFNγ enhances several CSC phenotypes, such as resistance to chemo- and radiotherapy and metastasis formation. We identified the branched-chain amino acid aminotransaminase 1 (BCAT1) as a downstream mediator of IFNγ-induced CSC plasticity. Targeting BCAT1 in vivo improved cancer vaccination and ICB therapy by preventing IFNγ-induced metastasis formation. Breast cancer patients treated with ICB exhibited a similar increase in CSC markers expression indicating comparable responses to immune activation in humans. Collectively, we discover an unexpected, pro-tumoral role for IFNγ that may contribute to cancer immunotherapy failure.

1 February 2018 in Cell
Verified
Journal Article
Closed access
JHJoerg Huelsken
Joerg Huelsken
DHDouglas Hanahan
Douglas Hanahan